March 15, 2021 -- ElevateBio has raised $535 million in financing to advance its cell and gene therapy (CGT) technology platforms, build its network of process development and good manufacturing practice (GMP) manufacturing capacity, and increase its number of industry partnerships.
ElevateBio has created a suite of CGT-enabling technologies, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering technologies. The company is advancing CGTs using its technology-enabled process development and current GMP (cGMP) manufacturing capability, called BaseCamp.
Matrix Capital Management led the series C financing.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
